Evidence map›Paper›PMID 27362259›Full record

ArticlePloS one2016

Profiling Analysis of Histone Modifications and Gene Expression in Lewis Lung Carcinoma Murine Cells Resistant to Anti-VEGF Treatment.

Dong Li, Jiejun Shi, Yanhua Du, Kaiming Chen, Zhenping Liu, Bing Li, Jie Li, Fei Tao, Hua Gu, Cizhong Jiang and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Dong LiSchool of Life Sciences and Technology, Tongji University, Shanghai, 200092, China.
Jiejun ShiThe Collaborative Innovation Center for Brain Science, Shanghai Key Laboratory of Signaling and Disease Research, Tongji University, Shanghai, 200092, China.
Yanhua DuThe Collaborative Innovation Center for Brain Science, Shanghai Key Laboratory of Signaling and Disease Research, Tongji University, Shanghai, 200092, China.
Kaiming ChenSchool of Life Sciences and Technology, Tongji University, Shanghai, 200092, China.
Zhenping LiuThe Collaborative Innovation Center for Brain Science, Shanghai Key Laboratory of Signaling and Disease Research, Tongji University, Shanghai, 200092, China.
Bing LiThe Collaborative Innovation Center for Brain Science, Shanghai Key Laboratory of Signaling and Disease Research, Tongji University, Shanghai, 200092, China.
Jie LiSchool of Life Sciences and Technology, Tongji University, Shanghai, 200092, China.
Fei TaoSchool of Life Sciences and Technology, Tongji University, Shanghai, 200092, China.
Hua GuSchool of Life Sciences and Technology, Tongji University, Shanghai, 200092, China.
Cizhong JiangThe Collaborative Innovation Center for Brain Science, Shanghai Key Laboratory of Signaling and Disease Research, Tongji University, Shanghai, 200092, China.
Jianmin FangSchool of Life Sciences and Technology, Tongji University, Shanghai, 200092, China.
Tongji University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor cells become resistant after long-term use of anti-VEGF (vascular endothelial growth factor) agents. Our previous study shows that treatment with a VEGF inhibitor (VEGF-Trap) facilitates to develop tumor resistance through regulating angiogenesis-related genes. However, the underlying molecular mechanisms remain elusive. Histone modifications as a key epigenetic factor play a critical role in regulation of gene expression. Here, we explore the potential epigenetic gene regulatory functions of key histone modifications during tumor resistance in a mouse Lewis lung carcinoma (LLC) cell line. We generated high resolution genome-wide maps of key histone modifications in sensitive tumor sample (LLC-NR) and resistant tumor sample (LLC-R) after VEGF-Trap treatment. Profiling analysis of histone modifications shows that histone modification levels are effectively predictive for gene expression. Composition of promoters classified by histone modification state is different between LLC-NR and LLC-R cell lines regardless of CpG content. Histone modification state change between LLC-NR and LLC-R cell lines shows different patterns in CpG-rich and CpG-poor promoters. As a consequence, genes with different level of CpG content whose gene expression level are altered are enriched in distinct functions. Notably, histone modification state change in promoters of angiogenesis-related genes consists with their expression alteration. Taken together, our findings suggest that treatment with anti-VEGF therapy results in extensive histone modification state change in promoters with multiple functions, particularly, biological processes related to angiogenesis, likely contributing to tumor resistance development.

Indexed as

Drug Resistance, NeoplasmAnimalsCarcinoma, Lewis LungCell Line, TumorCpG IslandsEpigenesis, GeneticGene Expression ProfilingGene Expression Regulation, NeoplasticHistone CodeMicePromoter Regions, GeneticReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsafliberceptReceptors, Vascular Endothelial Growth FactorRecombinant Fusion Proteins

Identifiers

PMID27362259
PMCPMC4928805
OpenAlexW2466452385

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.